FDA to support new orphan drugs through pilot program
Companies developing drugs for rare diseases can apply to be part of a new FDA pilot program, starting at the beginning of the year.
- Media: This is why the FDA has reprimanded Novo Nordisk following US plant inspection
- FDA delays decision on chikungunya vaccine from Valneva
For subscribers